GSK swine flu drug approved in US: company

Nov 11, 2009

British drug maker GlaxoSmithKline has announced that US regulators have approved its swine flu vaccine for adults in the United States.

"The US Food and Drug Administration (FDA) has approved a... license application for its unadjuvanted influenza A (H1N1) pandemic vaccine," GSK said in a statement received on Wednesday.

"The United States Department of Health and Human Services has placed an order to fill 7.6 million doses of unadjuvanted H1N1 pandemic vaccine from GSK, which will contribute to the approximately 250 million doses secured by the US government."

Although the is used to fight swine flu, its make-up is different to Pandemrix -- GSK's drug recently approved by EU regulators to treat in Europe.

(c) 2009 AFP

Explore further: Supercomputers link proteins to drug side effects

add to favorites email to friend print save as pdf

Related Stories

Sanofi to deliver swine flu vaccine in October

Sep 21, 2009

(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.

FDA approves new swine flu vaccine

Sep 15, 2009

(AP) -- The Food and Drug Administration approved the new swine flu vaccine Tuesday, a long-anticipated step as the government works to get vaccinations under way next month. Health and Human Services Secretary ...

Recommended for you

Supercomputers link proteins to drug side effects

5 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

12 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0